secwatch / observer
8-K filed April 7, 2025, 7:59 PM ET CIK 0001492674
leadership confidence high sentiment negative materiality 0.95

T2 Biosystems loses entire board and top management; appoints turnaround specialist as CEO

T2 Biosystems, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Gibbs

Senior Vice President, General Counsel and Corporate Secretary
T2 Biosystems, Inc.
Effective
2025-03-18
Successor
Craig R. Jalbert
Filed
April 7, 2025, 7:59 PM ET
On March 18, 2025, Michael Gibbs notified the Company of his termination of that certain Consulting Agreement between himself and the Company, dated February 15, 2025 and his resignation from his position as the Company’s Senior Vice President, General Counsel and Corporate Secretary.
Departed

Laura Adams

Director
T2 Biosystems, Inc.
Effective
2025-04-03
Filed
April 7, 2025, 7:59 PM ET
On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.
Departed

John Sperzel

Chief Executive Officer and President
T2 Biosystems, Inc.
Effective
2025-03-31
Successor
Craig R. Jalbert
Filed
April 7, 2025, 7:59 PM ET
On March 31, 2025, John Sperzel notified the Company of his termination of that certain Consulting Agreement between himself and the Company, dated February 15, 2025 and his resignation from his position as the Company’s Chief Executive Officer and President.
Departed

John W. Cumming

Director
T2 Biosystems, Inc.
Effective
2025-04-03
Filed
April 7, 2025, 7:59 PM ET
On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.
Departed

Robin Toft

Director
T2 Biosystems, Inc.
Effective
2025-03-31
Filed
April 7, 2025, 7:59 PM ET
On March 31, 2025, John Sperzel and Robin Toft each notified T2 Biosystems, Inc. (the “Company”) of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof, effective immediately.
Departed

Seymour Liebman

Director
T2 Biosystems, Inc.
Effective
2025-04-03
Filed
April 7, 2025, 7:59 PM ET
On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.
Departed

David Elsbree

Director
T2 Biosystems, Inc.
Effective
2025-04-03
Filed
April 7, 2025, 7:59 PM ET
On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.
Departed

John Sprague

Chief Financial Officer and Corporate Treasurer
T2 Biosystems, Inc.
Effective
2025-04-03
Successor
Craig R. Jalbert
Filed
April 7, 2025, 7:59 PM ET
On April 3, 2025, John Sprague notified the Company of his resignation from his position as the Company’s Chief Financial Officer and Corporate Treasurer.
Departed

John Sperzel

Director
T2 Biosystems, Inc.
Effective
2025-03-31
Filed
April 7, 2025, 7:59 PM ET
On March 31, 2025, John Sperzel and Robin Toft each notified T2 Biosystems, Inc. (the “Company”) of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof, effective immediately.
Appointed

Craig R. Jalbert

Class I Director
T2 Biosystems, Inc.
Effective
2025-04-03
Filed
April 7, 2025, 7:59 PM ET
On April 3, 2025, the Board appointed Craig R. Jalbert, age 63, as a Class I director and the Company’s Chief Executive Officer, President, Corporate Treasurer, and Corporate Secretary, effective as of 11:30 a.m. on April 3, 2025.
Appointed

Craig R. Jalbert

Chief Executive Officer, President, Corporate Treasurer and Corporate Secretary
T2 Biosystems, Inc.
Effective
2025-04-03
Filed
April 7, 2025, 7:59 PM ET
On April 3, 2025, the Board appointed Craig R. Jalbert, age 63, as a Class I director and the Company’s Chief Executive Officer, President, Corporate Treasurer, and Corporate Secretary, effective as of 11:30 a.m. on April 3, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Gibbs resigned as Senior Vice President, General Counsel and Corporate Secretary at T2 Biosystems, Inc..

Action
resigned
Role
Senior Vice President, General Counsel and Corporate Secretary
Exact text from the filing
On March 18, 2025, Michael Gibbs notified the Company of his termination of that certain Consulting Agreement between himself and the Company, dated February 15, 2025 and his resignation from his position as the Company’s Senior Vice President, General Counsel and Corporate Secretary.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Laura Adams resigned as Director at T2 Biosystems, Inc..

Action
resigned
Role
Director
Exact text from the filing
On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

John Sperzel resigned as Chief Executive Officer and President at T2 Biosystems, Inc..

Action
resigned
Role
Chief Executive Officer and President
Exact text from the filing
On March 31, 2025, John Sperzel notified the Company of his termination of that certain Consulting Agreement between himself and the Company, dated February 15, 2025 and his resignation from his position as the Company’s Chief Executive Officer and President.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

John W. Cumming resigned as Director at T2 Biosystems, Inc..

Action
resigned
Role
Director
Exact text from the filing
On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robin Toft resigned as Director at T2 Biosystems, Inc..

Action
resigned
Role
Director
Exact text from the filing
On March 31, 2025, John Sperzel and Robin Toft each notified T2 Biosystems, Inc. (the “Company”) of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof, effective immediately.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Seymour Liebman resigned as Director at T2 Biosystems, Inc..

Action
resigned
Role
Director
Exact text from the filing
On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

David Elsbree resigned as Director at T2 Biosystems, Inc..

Action
resigned
Role
Director
Exact text from the filing
On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

John Sprague resigned as Chief Financial Officer and Corporate Treasurer at T2 Biosystems, Inc..

Action
resigned
Role
Chief Financial Officer and Corporate Treasurer
Exact text from the filing
On April 3, 2025, John Sprague notified the Company of his resignation from his position as the Company’s Chief Financial Officer and Corporate Treasurer.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

John Sperzel resigned as Director at T2 Biosystems, Inc..

Action
resigned
Role
Director
Exact text from the filing
On March 31, 2025, John Sperzel and Robin Toft each notified T2 Biosystems, Inc. (the “Company”) of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof, effective immediately.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Craig R. Jalbert was appointed as Class I Director at T2 Biosystems, Inc..

Action
appointed
Role
Class I Director
Exact text from the filing
On April 3, 2025, the Board appointed Craig R. Jalbert, age 63, as a Class I director and the Company’s Chief Executive Officer, President, Corporate Treasurer, and Corporate Secretary, effective as of 11:30 a.m. on April 3, 2025.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Craig R. Jalbert was appointed as Chief Executive Officer, President, Corporate Treasurer and Corporate Secretary at T2 Biosystems, Inc..

Action
appointed
Role
Chief Executive Officer, President, Corporate Treasurer and Corporate Secretary
Exact text from the filing
On April 3, 2025, the Board appointed Craig R. Jalbert, age 63, as a Class I director and the Company’s Chief Executive Officer, President, Corporate Treasurer, and Corporate Secretary, effective as of 11:30 a.m. on April 3, 2025.
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-25-073558
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.